GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00269126
- Locations
GSK Investigational Site
Use Of SB-705498 In The Acute Treatment Of Migraine
- Conditions
- Migraine, Acute
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00269022
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Integrated Biomarker And Imaging Study - 2
- Conditions
- Atherosclerosis
- Interventions
- Drug: SB-480848Drug: SB-480848 matching placebo
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 336
- Registration Number
- NCT00268996
- Locations
- 🇨🇭
GSK Investigational Site, Luzern 16, Switzerland
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Biological: Tositumomab and Iodine I 131 TositumomabBiological: Rituximab
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00268983
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, Lancashire, United Kingdom
SPECT Study With SB-773812 In Schizophrenic Patients
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 95
- Registration Number
- NCT00269035
- Locations
- 🇪🇸
GSK Investigational Site, Vic (Barcelona), Spain
SB-480848 In Subjects With Coronary Heart Disease
- Conditions
- Atherosclerosis
- Interventions
- Drug: SB-480848Drug: placebo
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2016-08-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 969
- Registration Number
- NCT00269048
- Locations
- 🇪🇸
GSK Investigational Site, Tarrasa, Barcelona, Spain
Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin
- Conditions
- Non-Insulin-Dependent Diabetes Mellitus
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00269061
- Locations
- 🇺🇸
GSK Investigational Site, Belmont, Massachusetts, United States
GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 122
- Registration Number
- NCT00269087
- Locations
GSK Investigational Site
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma, Non-Hodgkin
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 765
- Registration Number
- NCT00268203
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6228
- Registration Number
- NCT00268216
- Locations
GSK Investigational Site